Albumin-based nanomedicines, as representative examples, have been approved by the FDA and taken the lead in clinical practice to treat breast, lung, and pancreatic cancer, highlighting the great prospects of therapeutics in this category [160]. This evidence concerns the gene ALB and familial pancreatic carcinoma.